Timing of antimicrobial initiation and reduced infection risk in open limb fractures: a cohort study.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 04 11 2019
accepted: 19 01 2020
pubmed: 25 1 2020
medline: 5 1 2021
entrez: 25 1 2020
Statut: ppublish

Résumé

To assess whether early administration of antimicrobials in open fractures of the limbs reduces infection risk. A historical cohort study included all adult patients admitted with an open fracture of the limbs, between January 1, 2012, and December 31, 2016. Epidemiological, clinical, and microbiological data was collected and analyzed. Microbiological infection was defined by positive wound cultures during the first 30 days, and clinical infection as defined by the treating physician. Of 167 patients, microbiological infection was identified in 12 (7%) patients, and clinical infection in 27 (16%) patients. All patients received the first dose of antimicrobials within 15 h of admission (median 1.29 h). Very early administration of the first dose did not reduce the risk of infection (median of 1.06 h and 1.31 h for patients that did vs. did not develop infection, respectively P = 0.58). In multivariate logistic regression, location of fracture in the lower limbs was associated with an increased risk of infection (OR 4.654, CI 1.407-15.398), and Gustilo-Anderson classification grade 1 or 2 was associated with a decreased risk of infection (OR 0.301, CI 0.104-0.872). Very early administration of antimicrobials did not reduce risk of infection in open limb fractures.

Identifiants

pubmed: 31975314
doi: 10.1007/s10096-020-03825-8
pii: 10.1007/s10096-020-03825-8
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1077-1081

Auteurs

Sharon Reisfeld (S)

Infectious Diseases Unit, Hillel Yaffe Medical Center, Hadera, Israel. sharonr@hymc.gov.il.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. sharonr@hymc.gov.il.

Islam Labnawi (I)

Orthopaedic Surgery B, Hillel Yaffe Medical Center, Hadera, Israel.

Nurit Shadmi (N)

The Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Orthopaedic Surgery B, Hillel Yaffe Medical Center, Hadera, Israel.

Michal Stein (M)

Infectious Diseases Unit, Hillel Yaffe Medical Center, Hadera, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH